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| INTRODUC TI ON
Guidelines recommend lifelong anticoagulation in atrial fibrillation (AF) in the presence of stroke risk factors, 1,2 as well as in the secondary prevention of venous thromboembolism (VTE). 3, 4 Nonadherence to anticoagulation therapy is known to impact treatment outcomes, 5, 6 where adherence is defined as the extent to which a patient takes their medication as prescribed. 7 Time in therapeutic range (TTR) using the Rosendaal method indicates international normalized ratio (INR) control, where a TTR >65% is considered good and indicative of treatment adherence to vitamin-K antagonists (VKAs). 2, 8, 9 Low TTR has been shown to be associated with both poor adherence and worse clinical outcomes. 10, 11 Long-term VKA therapy presents unique challenges regarding medication adherence where patients may consider them cumbersome due to regular laboratory monitoring of INR, frequent dose changes, and variable dosing regimens while being restrictive regarding other drugs and foods. These factors may affect TTR, 12, 13 as well as treatment satisfaction and quality of life (QoL). 14 As TTR is routinely available to clinicians, it provides a means by which adherence can be objectively assessed.
Nonadherence is prevalent in chronic disease where up to 50% of patients are reportedly nonadherent. 15, 16 Unintentional nonadherence results from a lack of internal resources (capacity) or external resources (practical factors) inhibiting adherence. Intentional nonadherence involves a conscious underlying perceptual or motivational barrier to adherence, such as patient beliefs about an illness or medicines. 17, 18 Furthermore, behavior is influenced by one's capability to adhere, opportunity to adhere, and motivation to adhere, as described in the COM-B model of adherence, each factor being potentially modifiable. [19] [20] [21] Among those requiring chronic anticoagulation, patients may be asymptomatic and medication use is purely preventative. Therefore, drivers to adhere can be lacking. 22 While extensive research has been conducted to determine adherence to VKAs, 22 there is a paucity of research determining the impact of beliefs and QoL on adherence to VKAs and TTR. The
Switching Study is a program of work investigating the association between beliefs and TTR and longitudinal adherence in those who switch to a direct oral anticoagulant (DOAC). 23 The primary aim of this study is to investigate differences in the beliefs between those with optimal and suboptimal TTR. A secondary objective is to investigate whether beliefs and clinical demographic variables are associated with TTR.
| METHODS
This cross-sectional observational study was conducted in the outpatient setting across the two anticoagulation clinics of King's
College Hospital NHS Foundation Trust in South East London. The
Denmark Hill (DH) site is a tertiary center in a densely populated inner-city area with a skew in the population towards lower socioeconomic status. The Princess Royal University Hospital (PRUH), situated between London and Kent, has an affluent catchment with a predominantly elderly Caucasian population.
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A random sample of patients prescribed VKAs for AF or secondary prevention of VTE with a TTR >75% over the previous year were identified using the DAWN (4S Information Systems, Ltd., Cumbria, England) databases at each site and sent a questionnaire pack with a patient information leaflet describing the study, a consent form, a prepaid envelope by which to return the completed questionnaire pack, and a complimentary tea bag. Patients with TTR <50%, were also identified via the DAWN database and invited to a pharmacistled consultation in clinic. For the TTR <50% group, patients were purposively sampled, the questionnaire pack was sent by mail accompanied by a clinic appointment letter. Questionnaires were to be completed at baseline prior to their appointment where they were counselled and offered the opportunity to change anticoagulation therapy to a DOAC provided it was clinically appropriate to do so.
Patients who were switched to a DOAC for an unlicensed indication were done so under the instruction and supervision of a consultant hematologist. Patients were not incentivized to complete the questionnaire prior to their consultation and were made aware that participation in the study would not impact subsequent treatment decisions. TTR was calculated by the Rosendaal method and was measured over the previous 12 months. For those who had been prescribed VKAs for less than 12 months, the TTR over that entire period was used, provided they had been prescribed VKAs for more than 3 months.
Cut-offs of TTR <50% and TTR >75% were selected as a binary variable was required for logistic regression. The cut off for "good" control is typically set at 65%. 2, 8 As TTR is dynamic, extremes were opted for to determine clear differences between those with optimal control and those with poor control. Furthermore, research has demonstrated that compared to the poorly controlled cohort with a median TTR of 50%, those with a TTR >75% were far less likely to suffer a major event (HR = 0.164, P < .05). 25 As such, the decided cut-offs were deemed both clinically appropriate and statistically necessary.
Essentials
• Study comparing illness beliefs, treatment beliefs and treatment satisfaction according to TTR.
• TTR <50% associated with negative health beliefs compared to TTR >75%.
• Cluster analysis generated belief profiles, where different profiles were associated with TTR.
• Indicates beliefs that can be targets for interventions to improve adherence and TTR.
To be eligible for the study, patients needed to be: aged over 18, prescribed lifelong anticoagulation, VKA treatment duration greater than 12 weeks, capable of providing informed consent, and able to read English. Patients with active cancer, autoimmune disease, and metallic heart valves were excluded from the study.
Clinical and demographic data was collected and CHA 2 DS 2 VASc, CHADS 2 , HAS-BLED, Charlson comorbidity index (CCI), and SAMe-TT₂R scores calculated. [26] [27] [28] [29] [30] As the HAS-BLED scoring system for determining bleeding risk allocates 1 point for TTR <60% which is also the grouping variable, true HAS-BLED and adjusted HAS-BLED scores were calculated, where the adjusted HAS-BLED score discounts the point allocated for TTR <60%.
| Study tools
Illness beliefs, medication beliefs, and treatment satisfaction/
anticoagulation-specific quality of life were assessed using a question- confronted with health threats, coping mechanisms deconstruct the threat into various illness representations: identity, timeline acutechronic, timeline cyclical, consequences, personal control, treatment control, cause, illness control, and emotional distress. 31 The BMQ assesses beliefs regarding medication on four subscales; general harm and general overuse explore beliefs surrounding medication in general. Specific necessity determines the extent the patient recognises the need for VKA therapy, while the specific concern subscale determines how strong their anxieties towards VKAs are. 32 The ACTS measures anticoagulation-specific QoL and treatment satisfaction on two subscales: benefits and burdens of anticoagulation therapy. 33, 34 For descriptions of all subscales see Table 1 .
The Cronbach's alpha test for internal consistency was used on each of the questionnaire subscales where an alpha score >0.6 is considered reliable. 35 All subscales had Cronbach's α scores >0.6
other than treatment control where α = 0.407 and accidental cause α = 0.170, the latter being consistent with the validation study. 31 See Supplementary Table S1 .
| Statistical analysis
Data from completed questionnaires were analyzed using Statistical independent t tests were conducted to compare continuous variables including subscale scores. Non-normally distributed subscales would be compared using Wilcoxon-rank tests. Necessity-concerns differentials (NCDs) were calculated by subtracting the specific concerns subscale score from the specific necessity subscale score, where positive differentials indicate that necessity beliefs outweigh concerns. 36 All tests were 2-tailed with significance set at P ≤ .05.
Cluster analysis was performed on subscale scores to profile patients according to beliefs, other than causes subscales. Cluster analysis reduces the number of variables and groups subjects according to the entirety of their beliefs. Hierarchical cluster analysis using Ward's method with squared Euclidean distance for pairing of subjects was used. One-way analysis of variance (ANOVA) was undertaken to de- Each subscale had a mean score calculated to account for any missing answers. Subscales with six items were allowed a maximum of two missing answers while subscales with less than six items were allowed a maximum of one missing answer to be included in the final analysis. The ACTS burdens subscale required a minimum of 9 out of 12 answered questions to be included in analysis. TTR <50% patients who returned incomplete questionnaires were asked to complete the missed answers following the consultation and providing consent. TTR >75% patients
were not approached to complete incomplete questionnaires.
| Power calculation
Assuming a recruitment ratio of 1:1 of TTR >75%: TTR <50%, a total sample size of 180 to 240 patients would be able to accommodate 12 predictive variables for binary logistic regression; i.e., up to 120 patients with TTR >75% and up to 120 patients with TTR <50%. As TTR <50% patients would enter a longitudinal study which had a recruitment target of 240, a recruitment ratio of 1:1 was maintained for this study.
| Ethical approval
This study was reviewed and approved by the London-Dulwich
Research Ethics Committee (13/LO/1468) and King's College
Hospital NHS Foundation Trust research and development (KCH14-111).
| RESULTS
Between September 2014 and October 2016, 525 patients were recruited. Of 1049 questionnaires mailed to TTR >75% patients, 326 (31%) were returned and 15 of these were incomplete and not used. The identity section of IPQ-R was consistently poorly answered with many patients leaving several questions blank, therefore this section of the IPQ-R was not analyzed. Patients in TTR >75% were older and had been prescribed VKAs for longer than those with TTR <50% across all disease groups (P < .001 for all), see Table 2 . Among AF patients there were no differences in stroke risk as calculated by either CHADS 2 or CHA 2 DS 2 VASc between groups, nor was there any difference in adjusted HAS-BLED score between groups.
| Differences in beliefs
Amongst AF patients, those with TTR >75% had stronger chronic timeline beliefs and were less likely to believe that their illness was cyclical (Table 3 ). TTR <50% patients had greater concern about the consequence of their illness while also experiencing greater emotional distress because of their AF. TTR <50% patients reported believing more strongly in the potential for harm from pharmaceutical products accompanied by greater concerns regarding VKAs specifically, whilst perceiving it to be less necessary. According to both the benefits and burdens subscales, TTR <50% patients had lower treatment satisfaction.
For VTE patients, illness beliefs were broadly similar to AF patients with some key exceptions: TTR <50% patients have lower illness coherence and do not experience different levels of emotional distress. While TTR <50% VTE patients have greater concerns about VKAs, both groups have similar beliefs regarding the necessity of anticoagulation treatment. There were no differences in treatment satisfaction.
| Patterns of beliefs
Cluster analysis revealed four distinct belief sets (Table 4) . Cluster 1 were accepting of both their therapy and their illness, cluster 2 was cautious of therapy but accepting of their illness, cluster 3 was accepting of therapy but fearful about their illness, while cluster 4 was cautious of therapy and fearful of their disease. Clinical demographics according to cluster are shown in Table 5 . Cluster 1 was the most populous where patients were likely to be well controlled with VKAs.
Over 65% of patients in cluster 4 were poorly controlled on VKAs and over 50% of patients in this cluster were female compared to approximately 35% in all other clusters. Post hoc analysis of subscale scores showed significant differences between clusters in every subscale, validating the cluster analysis, see Supplementary Table S2 . an ACE-inhibitor or drug increasing bleeding risk, no thrombotic history, and belief cluster 1. The resulting model found that only diagnosis and belief cluster were associated with TTR <50% (Table 6 ). 
| Factors influencing TTR

| AF versus VTE
Comparing AF and VTE patients with TTR >75% (Table 7) revealed VTE patients have greater concerns about therapy, necessity beliefs, and burdens compared to AF patients. These VTE patients also had greater conviction in their illness being caused by accident or bad luck. AF patients with TTR >75% were more likely to attribute their illness to psychological causes such as stress, family problems, or overwork. AF patients were also more likely to believe that their illness was caused by risk factors such as genetics, unhealthy eating, and poor medical care.
Comparing AF and VTE patients with TTR <50% demonstrated that VTE patients had greater specific necessity beliefs relating to VKAs and were more likely to recognize the benefits of therapy than AF patients. Although compared to AF patients, VTE patients reported greater burdens of VKA therapy, this was not statistically significant. Like those with TTR >75%, VTE patients in this group attributed their illness to accident or bad luck more frequently than AF patients. There were no significant differences in NCDs between AF and VTE in either optimal or suboptimal groups (Supplementary   Tables 3 and 4) .
| DISCUSSION
This study has demonstrated how illness beliefs, medication beliefs, and anticoagulation-specific QoL and treatment satisfaction differ between those with optimal (TTR >75%) and suboptimal (TTR <50%)
INR control. To our knowledge, this is the first study designed to examine the differing beliefs between these groups and to determine belief patterns associated with TTR. The differences in beliefs were largely similar for both the AF and VTE patients, albeit with some exceptions. In examining the differences between the two groups, there are two key aspects to this VKA experience: understanding and knowledge of illness and subjective experiences of their illness and treatment. 
TA B L E 5 Clinical and Demographic Characteristics of Clusters
TA B L E 6 Unadjusted Binary Logistic Regression Model Predicting TTR <50%
Odds ratio (OR) Diagnosis of AF and Cluster 1 were baseline comparators.
| Understanding and knowledge of illness
Despite all patients being prescribed VKAs lifelong, timeline beliefs were markedly different between groups. Those with TTR >75%
with either condition believed more strongly in the chronic and noncyclical nature of their illness. This accompanied by lower illness coherence among TTR <50% VTE patients, highlights a knowledge deficit among patients with TTR <50% about the course and nature of their illness.
Among AF patients, those with TTR <50% believed less in VKA necessity, indicating these patients may be less aware of the risk of stroke associated with AF and the role anticoagulation plays in preventing it. Conversely, VTE patients had similar necessity beliefs across the board. This is likely to be related to VKA therapy being the active treatment used for acute VTE and therefore they placed a higher value on VKA treatment for secondary prevention.
Research elsewhere has demonstrated that a strong sense of necessity, is linked to better adherence while strong concerns have the opposite effect. 37 In practice, clinicians should elicit these beliefs at the outset to ensure appropriate understanding. Although interventions in anticoagulation that have targeted education alone have had limited success, 38, 39 there is scope to improve TTR by addressing inaccurate beliefs if combined with other behavior change techniques. Interventions utilising nonmedical personnel such as pharmacists and nurses have proved to be successful. 40 
| Subjective experiences of illness and treatment
AF patients with TTR <50% reported fewer benefits of anticoagulation and greater emotional distress, specific concerns and burdens of therapy, while TTR <50% VTE patients scored higher in specific concerns and trended towards greater burdens. This is indicative of negative experiences regarding emotional wellbeing and treatment satisfaction. This is consistent with Lane et al's work which found that high baseline specific concern was consistent with worse QoL. 41 It is likely that the experience of out- 
| Beliefs of AF and VTE patients
TTR >75% VTE patients had a greater recognition of the necessity for VKA therapy compared to those with AF, similar to findings in Dutch patients. 45 Unexpectedly, our VTE patients had greater concerns and reported more burdens related to VKAs. The NCDs between AF and VTE patients were similar in both groups. This is in contrast to previous research, which has found that VTE patients had higher differentials compared to AF patients. 45 A possible explanation for this is our VTE patients were on average 10 years younger and younger age has been associated with worse adherence elsewhere. 46, 47 Furthermore, as the AF population was more comorbid, VTE patients were likely to recognize the burden of their illness more than AF patients where AF is one of many illnesses. Beyond this, although not statistically significant, VTE patients exhibited stronger consequence beliefs regarding their illness. As all VTE patients had experienced a symptomatic event previously, this heightened risk perception compared to AF patients is intuitive. Kaptein et al previously reported that among those at high risk of thrombosis, those who had previous experience of a thrombus had significantly higher risk perception. 48 This could explain the raised necessity and consequence perceptions in VTE.
| Validity of study tools
The high internal consistency through Cronbach's alpha validates the use of the IPQ-R, BMQ, and ACTS for use in AF and VTE patients prescribed VKAs. 35 The exceptions were the accidental cause of the treatment control subscales. The latter is mitigated through the analogous subscales from the BMQ and ACTS questionnaires and was not improved by removing any one question from the subscale. The alpha score for accidental cause is similar to that of the validation study for IPQ-R and is low due to there being only two questions in the subscale. 
| Limitations
While low TTR is associated with poor adherence to VKAs, it is not the only cause. Other factors include dietary intake, other medication, genetic polymorphism, or inappropriate VKA dosing. This is a noninterventional study and all TTR <50% patients were asked to complete their questionnaire prior to consultation to prevent bias; however, some incomplete questionnaires were submitted. In this case patients were asked to be complete missing answers after the consultation, potentially affecting the results in a small number of patients. This study also does not provide insight into beliefs about VKAs in the context of the patient's other medication. Due to the cross-sectional nature of this study, the beliefs of patients with TTR between 51% and 74% are unknown.
| CONCLUSIONS
This study has demonstrated that illness beliefs, medication beliefs, and QoL in patients prescribed chronic VKA therapy are significantly associated with the behavior of anticoagulated patients and are associated with INR control. The multiple disparities between those with TTR >75% and TTR <50% groups can be targeted through theory-driven interventions to attempt improving TTR and support medication adherence. 
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